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3 groups based on receipt of cardiac catheterization (cath) < 12 hours of lytics (early 
cath,N=261), > 12h after lytics (late cath,N=451) or no cath (conservative treat- 
ment,N=1056). The likelihood of in-hospital mortality and reinfarction was determined 
using multivariate analysis. 
Results: 41% pts underwent cath during index hospitalization. 89% of eady cath pts had 
a PCI (pemutaneous coronary intervention) as opposed to 61% of the late cath group (p 
< 0.0001). The outcomes of the early cath group did not differ significantly from the lyrics 
only group. However, the incidence of in-hospital death was significantly lower in the late 
cath group as compared to the lytics only group (2% Versus 6.8%, p 0.0002). This 
remained true even after controlling for differences in baseline and in-hospital character° 
istics between the 2 groups (late oath mortality OR 0.3, 95%CI 0.13-0.63). The likelihood 
of a reinfarction was, however, significantly high in the late cath group. 
Conclusions: Although lytics substantially reduce mortality after an acute STE MI many 
pts may derive an additional benefit from the use of a cardiac cath and, if indicated, a 
PCI, especially if performed non-urgently. 
Odds of death and reinfarction during Index hospitalization 
(* compared with lytlcs only group) 
DEATH DEATH REINFARCTION REINFARCTION 
OR 95%CI OR 95%CI 
Late Cath 0.3 0.13-0.63 3.1 1.78-5.23 
Cath 0.5 0.27-0.79 2.5 1.49-4.25 
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822 Cardiac and Systemic Markers as 
Predictors of Risk in Acute Coronary 
Syndromes 
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Georgia World Congress Center, Room 264W 
2:00 p.m. 
822-1 Elevated White Blood Cell Count Is Associated With 
Higher Mortality in Patients With Acute Coronary 
Syndromes Independent of Other Cardiac Markers: A 
TACTICS - TIM118 Substudy 
Marc S. Sabatine. David A. Morrow, Sabina A. Murphy, Laura A. Demopoulos, Peter M. 
DiBattista, Carolyn H. McCabe, Christopher P. Cannon, Eugene Breunwald, Michael 
Gibson, Brigham and Women's Hospital, Boston, Massachusetts. 
Background & Methods: Higher white blood cell counts (WBCC) have been associated 
with higher mortality in the setting of acute coronary syndromes (ACS). We sought to 
examine if this relationship was true independent of other cardiac markers of inflamma- 
tion and/or infarction in TACTICS - TIM118. 
Results: The median WBCC (103/ram 3) at baseline was 8.1 [interquartile range (IR) 6.7- 
10.1]. Median WBCC was higher in patients who died by 30 days (9.1, IR 7.8-12 vs. 8.1, 
IR 6.6-10.1; p=0.0016) and 180 days (8.75, IR 7.6-10.95 vs. 8.1, IR 6.6-10.1; p=0.0047). 
Of the 1841 patients with WBCC & C-reactive protein (CRP) data, patients with a low 
WBCC (<25 th percentile) and a low CRP (<1.5 mg/dL) had a 6-month mortality rate of 
0,7%, those with a low CRP but a high WBCC had a rate of 2.8%, and those with a high 
CRP regardless of WBCC had a mortality rate of 6.2% (p<0.0001, Z 2 for trend). In a Cox 
proportional hazards model adjusted for age, smoking, craatinine, prior MI, prior aspirin 
use, troponin level, and ST deviation, patients with low CRP but high WBCC remained at 
significantly higher risk of death at 180 days [hazard ratio (HR) 5.4, p=0.02], and patients 
with high CRP were at even higher risk (HR 12.2, p=0.0007). 
Conclusion: Higher baseline WBCC are associated with a higher risk of 6-month mortal- 
ity. Even after adjusting for traditional risk factors, including troponin and ST deviation, 
assessment of two inflammatory markers, WBCC and CRP, can be used to stratify 
patients with ACS into low, intermediate, and high 6-month mortality risk. 
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822-2 Elevated C Reactive Protein (CRP) Is Associated With a 
Higher Risk of Thrombotic Occlusion and Poorer Flow 
Following Percutaneous Coronary Intervention in 
Patients With Acute Coronary Syndromes: A TACTICS 
TIM118 Angiographic Substudy 
Michael Gibson, David Morrow, Ralph Vicari, Graham Wong, Laura Demopoious, Peter 
DiBattista, Sabina A. Murphy, Chdstopher P. Cannon, Eugene Braunwald, Harvard 
Clinical Research Institute, Boston, Massachusetts, Brigham and Women's Hospital 
Boston, Massachusetts. 
Background & Methods: Higher CRP levels are associated with a higher risk of cardiac 
events. The relationship between baseline CRP and angiogrephic findings has not been 
explored. In the TACTICS / TIMI 18 trial of invasive versus conservative strategies in the 
management of ACS, we hypothesized that elevations in CRP would be associated with 
unfavorable angiogrephic findings such as a higher risk of thrombotic occlusion. Results: 
Patients with a closed artery (TIMI Flow Grade (TFG) 0/1) had higher CRPs than patients 
with an open artery (TFG 2/3) (1.98 _+ 2.7 mg/dL, n=63 vs 1.22 + 1.8 mg/dL, n=392, 
p=0.005), and conversely a CRP > 2X the threshold (> 3.0 mg/dL) was associated with a 
higher risk of thrombotic occlusion (26.8%, 15/56 vs 12.0%, 48/399 p=0.003). Likewise, 
an elevated CRP > 2X threshold was associated with higher (i.e, slower) Corrected TIMI 
Frame Counts (CTFCs) on diagnostic catheterization (58.2 + 36.6, median 45.3, n=41, 
vs 43.1 + 30.6, median 32, n= 341, p=0.037 comparing medians). Even among patients 
who were troponin negative, those pts with a closed artery had a higher CRP compared 
to those with an open artery (1.84 _+ 2.4, n=10 vs 0.78 + 1.5, n=156, p=0.04) and again a 
CRP > 2X the threshold was associated with a higher risk of thrombotic occlusion 
(30.0%, 3/10 vs 4.5%, 7/156 p=0.001 ). Pts. who did not achieve TFG 3 following percuta- 
neous coronary intervention (PCI) had higher CRP levels (2.25 .t: 3.5 mg/dL, n=19 vs 
1.31 _+ 1.9 mg/dL, n=356, p=O.05), and likewise a CRP > 2X threshold tended to be asso- 
ciated with a lower incidence of TFG 3 after PCl (89.6%, 43/48, vs95.7%, 313/327, 
p=O.07). Those pts with no reflow or distal embolization during PCI had higher CRP lev- 
els (2.81 + 3.5, n=9 vs 1.33 + 2.0, n=367, p=0.034). There was no association between 
CRP and either disease extent (1,2,3 vessel disease) or tissue level perfusion as 
assessed using the TIMI Myocardial Perfusion Grade. Conclusions: Higher baseline 
CRP values are associated with a higher risk of thrombotic vessel occlusion on diagnos- 
tic cardiac catheterization and a lower incidence of TIMI 3 Flow after PCI. 
2:30 p.m. 
822-3 Ef fect  o f  A torvasts t in  on C-React ive Prote in in Patients 
With Acute Coronary Syndromes: A Substudy of the 
MIRACL Trial 
Scott Kinlav. Neder Rifai, Peter Libby, Peter Ganz on behalf of the MIRACL Investigators, 
Brigham and Women's Hospital Boston, Massachusetts, Children's Hospital Boston, 
Boston, Massachusetts. 
Background: Coronary lesions of patients with acute coronary syndromes are charac- 
terized by intense inflammation. The MIRACL trial showed that atorvastatin 80 mg/day 
reduced recurrent ischemic events in the first 16 weeks. The purpose of this study was to 
determine whether intensive lipid lowering can reduce serum C-reactive protein (CRP), a 
marker of inflammation, in patients with unstable angina or non-Q-wave MI. Methods: 
Blood samples were collected at baseline and at 16 weeks from 2,322 of 3,086 patients 
participating in the MIRACL trial. C-reactive protein (CRP) was measured by a highly 
sensitive immunoassay. The change in CRP was compared between patients randomly 
assigned to atorvastatin vs. placebo. The change in CRP was also evaluated separately 
in patients with unstable angina and non-Q-wave myocardial infarction. Results: The 
baseline median CRP was similar in the patients assigned to atorvastatin (10.0 mg/L) 
and placebo (9.9 mg/L), (p=NS). The reduction in CRP over 16 weeks of treatment was 
significantly greater in patients on atorvastatin (-7.5 mg/L) compared to placebo (-6.0 mg/ 
L, p<0.001). Atorvastatin led to a greater reduction in CRP in patients with non-Q-wave 
MI (-15.9 vs -10.0 mg/L, atorvastatin vs. placebo, p=0.011), as well as in patients with the 
unstable angina (-3.5 vs -2.5 rag/L, atorvastatin vs. placebo, p=0.003). Conclusion: 
Atorvastatin (80mg/day) reduced CRP, a marker of inflammation, in patients with acute 
coronary syndromes. This was observed in patients with non-Q-wave MI as well as 
unstable angina. Thus, in patients with acute coronary syndromes, atorvastatin reduces 
inflammation, a mechanism associated with plaque stabilization. This effect may contrib- 
ute to the clinical benefit observed in the MIRACL trial. 
2:45 p.m. 
822-4 Detection of Cardiac Neurohormonal Activation 
Complements Cardiac Troponin for Predicting 
Recurrent Events in UA/NSTEMh Prognostic Utility of 
BNP in TACTICS-TIM118 
David A. Morrow. James A. de Lemos, Marc S. Sabatine, Sabine A. Murphy, Peter M. 
DiBattiste, Carolyn H. McCabe, Christopher P. Cannon, Eugene Braunwald, Brigham & 
Women's Hospital Boston, Massachusetts. 
B-type natriuretic peptide (BNP) is released in response to increased ventdcular wall 
stress. Recent findings indicate that plasma levels of BNP predict mortality among 
patients (pts) with unstable angina & non-ST elevation MI. However, data in this popula- 
tion, and in combination with cardiac troponins are few. METHODS: Baseline levels of 
BNP (Biosite Diagnostics) and cTnl (Bayer Diagnostics) were available for 1541 pts with 
non-ST elevation ACS randomized to early invasive(INV) vs. conservative(CONS) man- 
JACC March 6, 2002 
agement in the TACTICS-TIM118 trial. Decision-limits of 80 pg/ml for SNP and 0.1 ng/ml 
for cTnl were pre-specified based on prior work. RESULTS: Pts with baseline BNP > 80 
ng/ml (n = 310) were at significantly higher risk of death by 30 days (5,2 vs. 1.2%, 
p<0.00Of) and 6 months (8.7 vs. 1.7%, p<0.0O01) after presentation. BNP predicted 
mortality independently of age, ST-segment depression, cTnl result, history of CHF and 
Killip class at presentation (p<0.0001). Importantly, BNP identified patients with negative 
oTnl who were at high risk for death (p=0.004) and death/MI (p=0.008) [FIG]. There was 
no significant difference in the benefit of INV vs. CON therapy among pts with positive vs. 
negative BNP with respect to deatWMI at 30 and 180 days (p-interaction >0.5). CON- 
CLUSIONS: BNP adds complementary information to cardiac troponin for risk assess- 
ment in unstable angina/non-ST elevation MI. Future research should aim at 
interventions which may reduce the risk associated with increased BNP. 
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The Inter-Relationship Between Creatinine Clearance, 
Cardiac Troponin T And Outcomes in Patients With 
Acute Coronary Syndromes 
Ronnier J. Aviles. Arman T. Askari, E. Magnus Ohman, Kenneth W. Mahaffy, L. Kristin 
Newby, Peter Berger, Gang Jia, Robert M. Califf, Bertil Lindahl, Lars Wallentin, Eric J. 
Topoi, Michael S. Lauer, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Although abnormal cardiac troponin T (TnT) is predictive of poor outcome, 
the prognostic value of cardiac troponin T in patients with renal impairment remains contro- 
versial. 
Methods: In GUSTO IV, 7800 with ACS were randomized to treatment with placebo, abcix- 
imab for 24 hours, or abciximab for 48 hours. The study cohort comprised 7637 subjects 
with complete TnT, creatinine clearance (CCI), and clinical data. Baseline TnT and CCI 
were analyzed. CCI was evaluated as categorical and as a continuous variable. Abnormal 
TnT: TnT > 0.1 mg/dL; abnormal CCI: CCI < median CCI (76 ml/min.). End point: composite 
of 30-day death and MI. 
Results: Death/MI occurred in 648 subjects. There were 126 (6%) events in patients with 
abnormal TnT, 140 (8%) events in patients with abnormal CCI, and 311 (15%) in subjects 
with both abnormal TnT/CCI. The highest risk of death/MI occurred in patients with both 
abnormal TnT/CCI (OR, 4.4; 95% CI, 3.4 - 5.7; P < 0.001), suggesting that abnormal TnT is 
predictive of outcome in patients with abnormal CCI. Even after adjusting for age > 65 yrs, 
weight > 90 kg, ST depression, history of angina, MI, CHF, diabetes, hyperlipidemia, HTN, 
smoking, PCI, CABG, stroke, and treatment with lib/Ilia, patients with both abnormal TnT/ 
CCI had the highest risk of death/MI (OR, 3.3; 95% CI, 2.5 - 4.5; P < 0.001). TnT was pre- 
dictive of outcome across the entire spectrum of CCI (Figure 1 ). 
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Conclusion: The prognostic value of TnT is not decreased in patients with impaired renal 
function who present with suspected ACS. 
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822-6 Elevated Serum Myoglobin Is Associated With 
Increased Long-Term Mortality, Independent of Cardiac 
Troponin I, Electrocardiographic Variables, and Other 
Baseline Variables: Combined Analyses From TIM111B 
and TACTICS/TIM118 
James A. de I._emos. David A. Morrow, Michael Gibson, $abina A. Murphy, Nader Rifai, 
Mark S. Sabatine, Howard A. Cooper, Carolyn H. McCabe, Elliott M. Antman, 
Christopher P. Cannon, Eugene Braunwald, University of Texas Southwestern Medical 
School, Dallas, Texas, TIMI Study Group, Boston, Massachusetts. 
Myoglobin (MYO) is a sensitive, but nonspecdic early marker of myocardial injury. Few 
studies have considered the prognostic implications of increased MYO among pts with 
non-ST elevation acute coronary syndromes (ACS). 
Methods: Baseline levels of MYO, cTnl, and CKMB were measured in 616 pts from TIMI 
11B and 1841 pts from TACTICS/TIMI t 8 (ACS:180, Bayer Diagnostics). Mortality at 6 
months was compared between pts with MYO levels above and below the recommended 
diagnostic threshold (110 ~g/L). 
Results: Pts with elevated baseline MYO were older, more often male, and more likely to 
present with MI (vs unstable angina), ECG changes, increased CKMB and increased 
cTnl (p<0.01 for each variable). In multivariate analyses adjusting for index diagnosis, 
baseline variables, ECG changes, cTnl, and CKMB, elevated baseline MYO remained 
associated with higher 6-month mortality: TIMI 11B adjusted OR 2.9 [1.2-7.0]; TACTICS/ 
TIMI 18 adjusted OR 2.7 [1.4-5.2]; combined dataset adjusted OR 2.8 [1.7-4.7]. There 
was no consistent association between MYO and nonfatal MI or recurrent ischemic 
events. 
Conclusions: In two distinct groups of pts with ACS, elevated baseline myoglobin was 
associated with a statistically significant near 3-fold increase in the risk for long-term mor- 
tality, independent of other baseline risk predictors, including age, diabetes, ECG 
changes and biomarkers such as cTnl and CKMB. These findings suggest that myoglo- 
bin should be added to the panel of biomarkere routinely measured in pts with ACS. 
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828 Enhancing Fibrinolysis: Combination 
With Newer Antiplatelet and 
Antithrombotic Agents 
Monday, March 18, 2002, 2:00 p.m.-3:30 p.m. 
Georgia World Congress Center, Room 256W 
2:00 p.m. 
828-1 Prevention of Reinfarction Using Half-Dose Reteplase 
and Abciximab: Observation From the GUSTO-5 Trial 
E. Maanus Qhman, Robert M. Califf, Michael Lincoff, Paul Armstrong, Neal Kleiman, 
Judith Hochman, Harvey White, Stefano Savonifto, Marion Piedmonte, Joan Booth, Eric 
J. Topoi, The University of North Carolina, Chapel Hill, North Carolina, The Cleveland 
Clinic Foundation, Cleveland, Ohio. 
Background: An important caveat to successful reperfusion in acute myocardial infarction 
has been reinfarction occudng early after administration of fibrinotytic therapy. Reinfarc- 
tions are associated with major morbidity and a high mortality. The impact of newer com- 
bination reperfusion therapies on reinfarction rates remains to be determined. Methods: 
We examined the rate of reinfarction among patients randomized to either r-PA (10+10u) 
or low-dose r-PA (5+5u) and full dose abciximab in the GUSTO-5 trial. Results: A total of 
479 patients (2.9%) had a reinfarction through discharge or 7 days, whichever was 
sooner. Patients randomized to combination therapy had significantly lower rate of reinf- 
arction compared with r-PA alone (2.3% vs 3.5%, p<O.0001). Reinfarctions within the first 
24 hours of randomization were more common among patients treated with r-PA (29% of 
all patients with reinfarctions after r-PA) compared with combination therapy (19%). Cer- 
tain baseline characteristics were more common among patients with reinfarction versus 
those without, such as the elderly (over 75 years: 19% vs 13%), females (30% vs 25%), 
and in patients with prior MI (24% vs 15%), but less common among current smokers 
(33% vs 46%). In an adjusted analysis, patients randomized to combination therapy were 
less likely to suffer reinfarction (Odds Ratio: 0.67 95%Ch 0.56-0.80, p<0.001) compared 
to r-PA alone, even among patients who were more likely to have reinfarction such as 
older patients (p<O.O01), and those with previous M I (p<0.O01). Conclusions: Combina- 
